Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in Chinese Pediatric and Young Adult Patients With Relapsed or Refractory B-cell ALL
NCT04156659Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Primary endpoint: Overall Remission Rate at 3 months. Planned start Nov 2021; status: withdrawn.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04156659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156659.